Back
covid-19
1 min read

[Newsletter] XENONEWS

  • Bertrand Fabien
  • Author Bertrand Fabien
  • Published 26 janvier 2022

Related Posts

XENOTHERA therapeutic farm, unique in France and across Europe, is featured in a major report published by Les Échos Week-End on April 24, 2026

Our 500 animals are raised under exceptional sanitary conditions, with one ambition: paving the way for animal-to-human organ transplantation. The report highlights the concrete challenges of xenotransplantation in France. It also showcases what XENOTHERA, at the heart of the XENOCURE consortium, is already developing today, notably its LIS1 antibody, administered during allografts to neutralize the immune system’s immediate response. It has received orphan drug designation in both the United States and Europe.

Read More

[Press Information] Orphan designation by the European Medicines Agency for LIS1, the transplant induction therapy from XENOTHERA

July 11th, 2022. # Download our press information (english version) # Télécharger...

Read More

[Press Alert] XENOTHERA announces the efficacy of its XAV-19 antibody against the BQ.1.1variant.

December 19, 2022. # Download our press alert (english version) # Télécharger...

Read More

XENOTHERA

21 rue La Nouë de Fer, 44200 Nantes, France

contact@xenothera.com

Media : xenothera@akkanto.fr
Linkedin-in